Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Purple Biotech (PPBT) Non Operating Income (2018 - 2025)

Purple Biotech has reported Non Operating Income over the past 4 years, most recently at $1.1 million for Q4 2022.

  • Quarterly Non Operating Income rose 8576.92% to $1.1 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $843000.0 through Dec 2022, up 880.56% year-over-year, with the annual reading at $966000.0 for FY2025, 74.07% down from the prior year.
  • Non Operating Income was $1.1 million for Q4 2022 at Purple Biotech, up from -$232000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $1.1 million in Q4 2022 and troughed at -$3.1 million in Q4 2018.
  • The 4-year median for Non Operating Income is -$42500.0 (2021), against an average of -$285700.0.
  • The largest YoY upside for Non Operating Income was 8576.92% in 2022 against a maximum downside of 393.62% in 2022.
  • A 4-year view of Non Operating Income shows it stood at -$3.1 million in 2018, then soared by 83.0% to -$522000.0 in 2019, then soared by 102.49% to $13000.0 in 2021, then soared by 8576.92% to $1.1 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Non Operating Income are $1.1 million (Q4 2022), -$232000.0 (Q3 2022), and -$38000.0 (Q2 2022).